Sector Chart Allogene Therapeutics, Inc.

Stocks

ALLO

US0197701065

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2026-07-31 EDT			5-day change	1st Jan Change
1.880 ^USD	-4.57%		+8.05%	+37.23%

07-29	Allogene Therapeutics' Cemacabtagene Ansegedleucel Receives FDA RMAT, Fast Track Designations	MT
07-29	Allogene Therapeutics, Inc. Receives FDA Regenerative Medicine Advanced Therapy And Fast Track Designations For Cemacabtagene Ansegedleucel As First-Line Consolidation Therapy For Large B-Cell Lymphoma	CI

Total Return

"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes

Sector Bio Therapeutic Drugs

	Capi.	Sales Growth	Profitability	Finances	EV / Sales	P/E
ALLOGENE THERAPEUTICS, INC.	649M	-	-	-	-	-
WUXI APPTEC CO., LTD.	56.54B
ARGENX SE	53.6B
BIONTECH SE	22.91B					-
INSMED INCORPORATED	21.37B					-
WUXI BIOLOGICS (CAYMAN) INC.	20.27B